Home » Topics » BioWorld Science

BioWorld Science
RSS

ATR kinase blockade useful for treating pancreatic ductal adenocarcinoma

Jan. 19, 2022

MAO mutant zebrafish exhibit abnormal brain development

Jan. 19, 2022

SUW-133 diminishes HIV viral load in vivo

Jan. 18, 2022

Avacta selects FAP-targeted proteasome inhibitor for preclinical development

Jan. 18, 2022

4basebio and eTheRNA collaborate to evaluate linear DNA for mRNA production

Jan. 18, 2022

ZIP8 found to correlate with severe rheumatoid arthritis

Jan. 18, 2022

MCC-1381, a pan-HDAC inhibitor with promising anticancer activity

Jan. 18, 2022

EZH2 as a promising therapeutic target for prostate cancer

Jan. 18, 2022

Ono and Neurimmune expand drug discovery collaboration for neurodegenerative diseases

Jan. 18, 2022

Researchers suggest ZEB2 targeting as an approach for atherosclerosis

Jan. 18, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...